BioCentury
ARTICLE | Clinical News

STI-001: Phase III data

January 25, 2016 8:00 AM UTC

A double-blind, Chinese Phase III trial in 501 patients with EGFR-expressing metastatic colorectal carcinoma showed that STI-001 plus irinotecan led to an ORR of 32.9%, PFS of 5.6 months and OS of 14....